Pharmaceuticals, Biotechnology and Life Sciences
Amryt has begun with “EASE”, the Phase 3 clinical trial of AP101, its lead drug candidate, which offers a potential treatment for a rare genetic skin disorder that causes fragile skin.
The U.S. Food and Drug Administration has approved Tesaro’s Zejula (niraparib) for the maintenance treatment (intended to delay cancer growth) of adult patients with recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer, whose tumors have completely or partially shrunk (complete or partial response, respectively) in response to platinum-based chemotherapy.
Alexion Pharmaceuticals’s Board of Directors has appointed Ludwig N. Hantson, Ph.D., as Chief Executive Officer and member of the Board of Directors, to succeed David R. Brennan, who has led the company as Interim CEO since December 2016.
Novo Nordisk’s new, fast-acting mealtime insulin for the treatment of diabetes in adults, Fiasp has been launched in Canada, following the recent marketing authorisation from Health Canada on 6 January 2017.
Inventiva, a biopharmaceutical company developing innovative therapies, particularly to treat fibrosis, has reported its financial results for the year ended December 31, 2016.
Bioventix, a UK company specialising in the development and commercial supply of high-affinity monoclonal antibodies for applications in clinical diagnostics, has reported unaudited interim financial results for the six-month period ending 31 December 2016.
Amryt, the pharmaceutical company focused on treatments for rare and orphan diseases, has appointed David Allmond as Chief Commercial Officer in a non-board capacity, with effect from 3 April 2017.
MDxHealth has reported results from a castration resistant prostate cancer (CRPC) treatment study.
Erytech Pharma, a French clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, has reported positive topline results from its Phase 2b clinical study evaluating its product candidate, eryaspase (GRASPA), in combination with chemotherapy for the treatment of second-line metastatic pancreatic cancer.
Eli Lilly plans to invest $850 million in its U.S. operations in 2017, the company said Friday.